<DOC>
	<DOCNO>NCT01315886</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy use novel dose conversion strategy switch immediate release oral opioids sublingual ( SL ) fentanyl ( Abstral ) treatment breakthrough cancer pain ( BTcP ) .</brief_summary>
	<brief_title>Conversion From Fast Acting Oral Opioids AbstralÂ®</brief_title>
	<detailed_description>The study aim show advanced stage cancer individual patient already high dos BTcP medication benefit start treatment high first dose SL fentanyl thus reduce number dose step insufficient pain relief .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Signed informed consent obtain . 18 year old , gender . Opioid tolerant patient Estimated frequency BTcP 0.54 time day . Treatment SL fentanyl within two week prior screen . Recent planned therapy would alter pain response analgesic . Treatment monoamine oxidase inhibitor &lt; 14 day concurrent SL fentanyl treatment . Significantly reduce liver and/or kidney function . Significant prior history substance abuse . Pregnancy , breast feed woman childbearing potential use adequate birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>sublingual</keyword>
	<keyword>fentanyl</keyword>
	<keyword>titration</keyword>
	<keyword>conversion</keyword>
	<keyword>breakthrough cancer pain</keyword>
	<keyword>pain intensity difference</keyword>
	<keyword>PID</keyword>
	<keyword>Edmonton Symptom Assessment System</keyword>
	<keyword>ESAS</keyword>
</DOC>